Search results
Your Path to Wealth: 3 Stocks Predicted to Double Your Investment by 2025
InvestorPlace via Yahoo Finance· 4 months agoToday, identifying investments with promising growth potential is a quest every investor undertakes....
3 Magnificent Growth Stocks to Buy in March
Motley Fool via Yahoo Finance· 2 months agoYou can find growth stocks in every sector. With healthcare making up nearly one-fifth of the U.S. economy, it's a great place to look. Three Motley Fool...
Moderna Stock: Bull vs. Bear
Motley Fool via Yahoo Finance· 2 months agoModerna (NASDAQ: MRNA) shot to stardom in the early days of the pandemic as it brought its coronavirus vaccine from drawing board to commercialization in...
If You Invested $10,000 in Moderna in 2019, This Is How Much You Would Have Today
Motley Fool via Yahoo Finance· 3 months agoModerna (NASDAQ: MRNA) shares skyrocketed in the early stages of the pandemic as the biotech company...
Moderna, Inc.'s (NASDAQ:MRNA) Intrinsic Value Is Potentially 92% Above Its Share Price
Simply Wall St. via Yahoo Finance· 6 months agoKey Insights The projected fair value for Moderna is US$151 based on 2 Stage Free Cash Flow to...
Moderna (MRNA) Beats on Q3 Earnings & Sales, Expects Lower COVID Demand
Zacks via Yahoo Finance· 6 months agoModerna (MRNA) beats expectations for earnings and sales. However, the company projects...
An Intrinsic Calculation For Moderna, Inc. (NASDAQ:MRNA) Suggests It's 46% Undervalued
Simply Wall St. via Yahoo Finance· 1 year agoKey Insights The projected fair value for Moderna is US$241 based on 2 Stage Free Cash Flow to...
5 Top Stocks to Buy in March
Motley Fool via Yahoo Finance· 2 months agoFrom artificial intelligence to renewed excitement in cryptocurrencies, there are a lot of phenomenal growth stories driving markets right now. But as...
Pfizer sees $10 billion-$15 billion in potential revenue from mRNA vaccines by 2030
Reuters via Yahoo News· 1 year agoIn November, Pfizer had raised its forecast for 2022 sales of its COVID-19 vaccine by $2 billion to...
Pfizer Expects $10-$15B From mRNA Vaccine Sales By 2030, Sees $17B Revenues Lost Due To Patent...
Benzinga via Yahoo Finance· 1 year agoAt Pipeline Day, Pfizer Inc (NYSE: PFE) forecasts annual revenue from its mRNA vaccine portfolio...
